Squarepoint
DFTX icon

Squarepoint’s Definium Therapeutics DFTX Stock Holding History

Squarepoint’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-125,522
Closed -$2.37M – 4758
2026
Q1 		$2.37M Buy
125,522
+80,120
+176% +$1.36M ﹤0.01% 2056
2025
Q4 		$608K Buy
+45,402
New +$562K ﹤0.01% 3052
2025
Q3 		– Sell
-19,684
Closed -$128K – 4743
2025
Q2 		$128K Sell
19,684
-3,787
-16% -$24.9K ﹤0.01% 4104
2025
Q1 		$137K Sell
23,471
-18,497
-44% -$132K ﹤0.01% 4131
2024
Q4 		$292K Sell
41,968
-38,153
-48% -$263K ﹤0.01% 4165
2024
Q3 		$456K Buy
+80,121
New +$557K ﹤0.01% 3170
2024
Q2 		– Sell
-57,650
Closed -$504K – 4435
2024
Q1 		$542K Buy
+57,650
New +$329K ﹤0.01% 2989
2022
Q3 		– Sell
-2,779
Closed -$27K – 3254
2022
Q2 		$27K Sell
2,779
-2,430
-47% -$30.7K ﹤0.01% 2756
2022
Q1 		$87K Buy
5,209
+2,889
+125% +$50.1K ﹤0.01% 2621
2021
Q4 		$48K Buy
2,320
+1,559
+205% +$49.8K ﹤0.01% 3027
2021
Q3 		$27K Buy
+761
New +$32.9K ﹤0.01% 2811

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Squarepoint's DFTX Position: Q2 2026 in Review

Squarepoint sold out of Definium Therapeutics (DFTX) in Q2 2026, closing a stake of 125,522 shares — an estimated $2.37M sold.

Squarepoint first reported a position in DFTX in Q3 2021 and held it in 11 quarters. The position peaked at $2.37M in Q1 2026. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Squarepoint reported no remaining Definium Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Squarepoint sold 125,522 Definium Therapeutics shares in Q2 2026, an estimated $2.37M.
  • Squarepoint first reported a position in Definium Therapeutics in Q3 2021 and held it in 11 quarters.
  • Squarepoint's Definium Therapeutics position peaked at $2.37M in Q1 2026.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.